Dr. David Alland, Director of the Rutgers New Jersey Medical School Public Health Research Institute, which is within the Rutgers Biomedical Health Sciences Institute for Infectious and Inflammatory Diseases, along with his colleagues Drs. Padmapriya Banada and Sukalyani Banik, have conducted the first evaluation of an innovative point-of-care test to detect COVID-19.
Dr. Alland, who is also the Chief of Infectious Disease at the Institue, says Cepheid, the molecular diagnostics company has received Emergency Use Authorization clearance of this test by the Food and Drug Administration.
Dr. Alland spoke with WBGO News Director Doug Doyle about why this test is special.
Click above to hear the entire interview.
